Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Burney Co.

Burney Co. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,623 shares of the biopharmaceutical company’s stock after selling 709 shares during the quarter. Burney Co.’s holdings in Gilead Sciences were worth $612,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GILD. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $25,000. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC increased its stake in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Quarry LP purchased a new stake in Gilead Sciences during the second quarter valued at about $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Barclays increased their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Wells Fargo & Company lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Mizuho increased their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Stock Performance

Shares of GILD opened at $91.84 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company’s fifty day moving average price is $91.85 and its 200 day moving average price is $83.81. The company has a market capitalization of $114.46 billion, a PE ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last ninety days. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.